About
Seasoned public health and global access advocate, with enterprise and strategic…
Activity
-
Just wrapped up an exciting episode of the State of Medtech with Omar M. Khateeb! It was a privilege to dive deep into the disruptive technology…
Just wrapped up an exciting episode of the State of Medtech with Omar M. Khateeb! It was a privilege to dive deep into the disruptive technology…
Liked by Mitra Corral
-
It was a great session with Lata Setty, Rachna Dayal, Christina Bui, Preethy Padmanabhan ,Karen Sheffield, MBA moderated by Milan C. and Reetu Gupta.…
It was a great session with Lata Setty, Rachna Dayal, Christina Bui, Preethy Padmanabhan ,Karen Sheffield, MBA moderated by Milan C. and Reetu Gupta.…
Liked by Mitra Corral
-
Celebrating a significant achievement in advancing Diabetes technology embecta technical Teams delivered a Masterclass in Innovation and product…
Celebrating a significant achievement in advancing Diabetes technology embecta technical Teams delivered a Masterclass in Innovation and product…
Liked by Mitra Corral
Experience
-
Freelance
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Publications
-
A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding
ClinicoEconomics and Outcomes Research
Despite hemostat use, uncontrolled surgical bleeding is prevalent. Drawbacks of current hemostats include limitations with efficacy on first attempt and suboptimal ease-of-use. Evarrest® is a novel fibrin sealant patch that has demonstrated high hemostatic efficacy compared with standard of care across bleeding severities. The objective of this study was to conduct a hospital cost analysis of the fibrin sealant patch versus standard of care in soft tissue and hepatic surgical bleeding.
Other authorsSee publication -
Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database
ClinicoEconomics and Outcomes Research
Bleeding remains a common occurrence in surgery. Data describing the burden of difficult-to-control bleeding and topical absorbable hemostat use are sparse. This study was conducted to estimate the clinical and economic impact that remains associated with uncontrolled surgical bleeding, even when hemostats are used during surgery.
Other authorsSee publication -
Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures
Journal of Medical Economics
A retrospective analysis of the Premier hospital database was used to identify adults who underwent brain/cerebral (BC), cardiovascular (CV: valve surgery and coronary artery bypass graft) and carotid endarterectomy (CEA) between January 2011-December 2012. Among these patients, those treated with SAPs were compared to those treated with SO. Propensity score matching (PSM) was used to create comparable groups to evaluate differences between SAPs and SO.
Read More:…A retrospective analysis of the Premier hospital database was used to identify adults who underwent brain/cerebral (BC), cardiovascular (CV: valve surgery and coronary artery bypass graft) and carotid endarterectomy (CEA) between January 2011-December 2012. Among these patients, those treated with SAPs were compared to those treated with SO. Propensity score matching (PSM) was used to create comparable groups to evaluate differences between SAPs and SO.
Read More: http://informahealthcare.com/doi/abs/10.3111/13696998.2015.1017503 -
An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is ‘Worth It’ In The Case Of Cancer
Health Affairs
We studied whether higher US cancer care costs, compared with those of ten European countries, were “worth it” by looking at the survival differences for cancer patients in these countries compared to the relative costs of cancer care.
Other authors -
-
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
J Clin Pharm Ther
Patients with sickle-cell disease (SCD) receiving chronic transfusions of red blood cells are at risk of developing serious adverse effects. Iron chelation therapy (ICT) helps eliminate iron overload by binding with plasma iron to form a non-toxic conjugate that can be safely excreted from the body. Two iron chelating agents are currently available in the United States: Deferoxamine (DFO) is an injectable formulation, and deferasirox (Exjade®) is an oral suspension. This study compared the…
Patients with sickle-cell disease (SCD) receiving chronic transfusions of red blood cells are at risk of developing serious adverse effects. Iron chelation therapy (ICT) helps eliminate iron overload by binding with plasma iron to form a non-toxic conjugate that can be safely excreted from the body. Two iron chelating agents are currently available in the United States: Deferoxamine (DFO) is an injectable formulation, and deferasirox (Exjade®) is an oral suspension. This study compared the frequency of hospitalizations, persistence and compliance of patients with SCD from Medicaid programmes treated with DFO vs. deferasirox.
Other authors -
-
Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck.
Current Medical Research and Opinion
Cetuximab (Erbitux*) is the only new medical therapy for locally and regionally advanced SCCHN to be licensed in industrialized countries in the past 15 years and presents an alternative to cisplatin which is the current therapeutic standard. In the absence of a published head-to-head trial, we estimated the relative benefit of cetuximab and cisplatin using an indirect comparison methodology.
Other authors -
-
Pharmacoeconomic considerations in treating iron overload in patients with β-thalassaemia, sickle cell disease and myelodysplastic syndromes in the US: a literature review.
Pharmacoeconomics.
Patients with β-thalassaemia, sickle cell disease (SCD) and myelodysplastic syndromes (MDS) require chronic blood transfusions, which can lead to iron overload and substantial morbidity and mortality. To reduce the excess iron and its deleterious effects, available iron chelation therapy (ICT) in the US includes oral deferasirox or infusional deferoxamine (DFO). The aim of this study was to review and synthesize the available pharmacoeconomic evidence on ICT in patients with β-thalassaemia, SCD…
Patients with β-thalassaemia, sickle cell disease (SCD) and myelodysplastic syndromes (MDS) require chronic blood transfusions, which can lead to iron overload and substantial morbidity and mortality. To reduce the excess iron and its deleterious effects, available iron chelation therapy (ICT) in the US includes oral deferasirox or infusional deferoxamine (DFO). The aim of this study was to review and synthesize the available pharmacoeconomic evidence on ICT in patients with β-thalassaemia, SCD and MDS in the US.
Other authors -
-
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.
J Clin Oncol
To determine the incidence and complications of myelodysplastic syndromes (MDS) among Medicare beneficiaries.
Other authors -
-
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Transfusion.
Patients with myelodysplastic syndrome (MDS) or severe anemia requiring repeated red blood cell (RBC) transfusions risk developing transfusional iron overload, which can reduce survival. Iron chelation therapy (ICT) has been shown to improve survival and quality of life in patients; however, ICT utilization in clinical practices is not well understood.
Other authors -
-
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
J Manag Care Pharm
Diabetes and hypertension are the 2 major causes of endstage
renal disease. The rate of chronic kidney disease (CKD) secondary to diabetes and/or hypertension is on the rise, and the related health care costs represent a significant economic burden.Other authors -
Organizations
-
Healthcare Business Women's Association
Board Member, Volunteer Engagement
- Present -
HBA
Pesident - NNJ Chapter
-
HBA
Pesident - SF Chapter
-
Impact100 Garden State
Member
-
Junior League of Morristown
Board Member
More activity by Mitra
-
I'm hiring! We're looking for a human rights expert to join our global sustainability team in Europe - the position will focus largely on EU programs…
I'm hiring! We're looking for a human rights expert to join our global sustainability team in Europe - the position will focus largely on EU programs…
Liked by Mitra Corral
-
Excited to be with our team at the first day of the #ESCcongress in London. Arrowhead Pharmaceuticals is here to showcase our latest innovations and…
Excited to be with our team at the first day of the #ESCcongress in London. Arrowhead Pharmaceuticals is here to showcase our latest innovations and…
Liked by Mitra Corral
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More